| Affiliation: | 1. Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;2. Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France;3. EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France;4. Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France;5. Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France;6. Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA;7. Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona, Spain;8. Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy;9. Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France;10. Oncologie Dermatologique, Centre Eugène Marquis, Rennes, France;11. Clinique de Dermatologie, Unité d''Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille, France;12. Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA;13. Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada;14. Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid, Spain;15. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;p. APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris, France;q. Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France;r. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;s. Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia |
